Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Takayasu Arteritis
NCT04161898Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2020
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in Takayasu arteritis (TAK) comparing Upadacitinib with Placebo (2 arms). Primary endpoints: Time to First Relapse of Takayasu Arteritis at 52 months and Number of Participants with Adverse Events at 58 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT04161898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161898.